Evidence map›Paper›PMID 34454894›Full record

Observational studyThe Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases

COVID-19-related hospital cost-outcome analysis: The impact of clinical and demographic factors.

Anna Miethke-Morais, Alex Cassenote, Heloisa Piva, Eric Tokunaga, Vilson Cobello, Fabio Augusto Rodrigues Gonçalves, Renata Dos Santos Lobo, Evelinda Trindade, Luiz Augusto Carneiro D Albuquerque, Luciana Haddad and 1 more

Open access · goldAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed, 1 pooled it
5.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 1 synthesis or guideline pooled it, 65 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Cost of illness studies in COVID-19: a scoping review.Cost effectiveness and resource allocation : C/E · 2024
    Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Anna Miethke-MoraisClinical Director´s Office, Hospital das Clínicas HCFMUSP, Faculty of Medicine, University of São Paulo, São Paulo, SP, Brazil.
Alex CassenoteDepartment of Gastroenterology, Faculty of Medicine FMUSP, University of São Paulo, São Paulo, SP, Brazil; Santa Marcelina Faculty, Discipline of Labour Market and Physician's Health, São Paulo, SP, Brazil; Medical Demography Study Group, Department of Preventive Medicine, Faculty of Medicine FMUSP, University of São Paulo, São Paulo, SP, Brazil.
Heloisa PivaExecutive Director´s Office, Instituto Central, Hospital das Clínicas HCFMUSP, Faculty of Medicine, University of São Paulo, São Paulo, SP, Brazil.
Eric TokunagaStrategy and Operations Department, Hospital das Clínicas HCFMUSP, Faculty of Medicine, University of São Paulo, São Paulo, SP, Brazil.
Vilson CobelloInformation Technology Department, Hospital das Clínicas HCFMUSP, Faculty of Medicine, University of São Paulo, São Paulo, SP, Brazil.
Fabio Augusto Rodrigues GonçalvesHealth Technology Assessment Center, Hospital das Clínicas HCFMUSP, Faculty of Medicine, University of São Paulo, São Paulo, SP, Brazil; Central Laboratory Division, Instituto Central, Hospital das Clínicas HCFMUSP, Faculty of Medicine, University of São Paulo, São Paulo, SP, Brazil.
Renata Dos Santos LoboLaboratory of Medical Investigation in Pathogenesis and Targeted Therapy in Onco-Immuno-Hematology (LIM-31), Faculty of Medicine FMUSP, University of São Paulo, São Paulo, SP, Brazil.
Evelinda TrindadeSão Paulo State Health Technology Assessment Network, REPATS-SES/SP, São Paulo State Health Secretariat, SP, Brazil; Hospital das Clínicas HCFMUSP, Faculty of Medicine, University of São Paulo, São Paulo, SP, Brazil.
Luiz Augusto Carneiro D AlbuquerqueDepartment of Gastroenterology, Faculty of Medicine FMUSP, University of São Paulo, São Paulo, SP, Brazil; Gastroenterology Department, Digestive Organs Transplant Division, Faculty of Medicine FMUSP, University of São Paulo, São Paulo, SP, Brazil.
Luciana HaddadDepartment of Gastroenterology, Faculty of Medicine FMUSP, University of São Paulo, São Paulo, SP, Brazil; Gastroenterology Department, Digestive Organs Transplant Division, Faculty of Medicine FMUSP, University of São Paulo, São Paulo, SP, Brazil. Electronic address: luciana.haddad@hc.fm.usp.br.
HCFMUSP Covid-19 Study Group
Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo · BRUniversidade de São Paulo · BRSecretaria da Saúde · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionAlthough patients' clinical conditions have been shown to be associated with coronavirus disease (COVID-19) severity and outcome, their impact on hospital costs are not known. This economic evaluation of COVID-19 admissions aimed to assess direct and fixed hospital costs and describe their particularities in different clinical and demographic conditions and outcomes in the largest public hospital in Latin America, located in São Paulo, Brazil, where a whole institute was exclusively dedicated to COVID-19 patients in response to the pandemic.

methodsThis is a partial economic evaluation performed from the hospital´s perspective and is a prospective, observational cohort study to assess hospitalization costs of suspected and confirmed COVID-19 patients admitted between March 30 and June 30, 2020, to Hospital das Clínicas of the University of São Paulo Medical School (HCFMUSP) and followed until discharge, death, or external transfer. Micro- and macro-costing methodologies were used to describe and analyze the total cost associated with each patient's underlying medical conditions, itinerary and outcomes as well as the cost components of different hospital sectors.

resultsThe average cost of the 3254 admissions (51.7% of which involved intensive care unit stays) was US$12,637.42. The overhead cost was its main component. Sex, age and underlying hypertension (US$14,746.77), diabetes (US$15,002.12), obesity (US$18,941.55), chronic renal failure (US$15,377.84), and rheumatic (US$17,764.61), hematologic (US$15,908.25) and neurologic (US$15,257.95) diseases were associated with higher costs. Age strata >69 years, reverse transcription polymerase chain reaction (RT-PCR)-confirmed COVID-19, comorbidities, use of mechanical ventilation or dialysis, surgery and outcomes remained associated with higher costs.

conclusionKnowledge of COVID-19 hospital costs can aid in the development of a comprehensive approach for decision-making and planning for future risk management.

Indexed as

COVID-19Hospital CostsAgedBrazilDemographyHospitalizationHumansProspective StudiesSARS-CoV-2CostCOVID-19Economic evaluationHealth economics

Identifiers

PMID34454894
PMCPMC8373618
OpenAlexW3195590130

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.